Overview

Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

Status:
Completed
Trial end date:
2018-05-18
Target enrollment:
Participant gender:
Summary
The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467
Phase:
Phase 2
Details
Lead Sponsor:
Arbutus Biopharma Corporation